Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07505810 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months | PHASE3 | NOT YET_RECRUITING | 880 | — | — | Mar 22, 2026 | Jan 1, 2028 | Apr 1, 2026 | - | — |
| NCT07505823 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months | PHASE3 | NOT YET_RECRUITING | 1,040 | — | — | Mar 22, 2026 | Jan 1, 2028 | Apr 1, 2026 | - | — |
| NCT07505836 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | PHASE3 | NOT YET_RECRUITING | 1,040 | — | — | Mar 22, 2026 | Jan 1, 2027 | Apr 1, 2026 | - | — |
| NCT07505888 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | PHASE3 | NOT YET_RECRUITING | 660 | — | — | Mar 22, 2026 | Nov 1, 2026 | Apr 1, 2026 | - | — |
seroconversion rates of Nm antibodies for serogroups A, C, Y, W135 at Day 30 after three-dose vaccination in baseline seronegative participants (pre-vaccination titer \<1:8)
GMTs of Nm antibodies for serogroups A, C, Y, W135 at Day 30 after three-dose vaccination in baseline seronegative participants (pre-vaccination titer \<1:8)
| Arm | Type | Description |
|---|---|---|
| experimental group | EXPERIMENTAL | - |
| active comparator group | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| experimental vaccine | BIOLOGICAL | Group ACYW135 Meningococcal Conjugate Vaccine |
| Active Comparator vaccine | BIOLOGICAL | Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) |
Inclusion Criteria: 1. Healthy participants aged 3 to 5 months. 2. The participant's legal guardian is capable of understanding and voluntarily signs the informed consent form. 3. Willing and able to comply with all scheduled visits, sample collection, vaccination, and other trial procedures. 4. Pr...